Editor: What To Know
- “The grant of this important patent in the US and Europe protects certain RSV fusion protein inhibitors discovered by ReViral, including lead pipeline asset RV521, and underscores the novelty of our RSV pipeline,” said Dr.
- , a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV), today announced that the United States Patent and Trademark Office (USPTO) recently granted patent US10,106,539 entitled “Spiro-Indolines for the Treatment and Prophylaxis of Respiratory Syncytial Virus Infection (RSV)”.
- Pre-clinical and clinical studies have shown that RV521 is a best-in-class inhibitor of RSV in adult volunteers.
April 8, 2019
ReViral Ltd., a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV), today announced that the United States Patent and Trademark Office (USPTO) recently granted patent US10,106,539 entitled “Spiro-Indolines for the Treatment and Prophylaxis of Respiratory Syncytial Virus Infection (RSV)”.
This composition of matter patent claims certain inhibitors of the fusion protein of the respiratory syncytial virus (RSV), including RV521, the Company’s lead pipeline asset. The counterpart to this patent, EP3204375, has also been issued in Europe.
“The grant of this important patent in the US and Europe protects certain RSV fusion protein inhibitors discovered by ReViral, including lead pipeline asset RV521, and underscores the novelty of our RSV pipeline,” said Dr. Eddy Littler, CEO of ReViral. “We look forward to progressing RV521 into international, pediatric Phase II clinical trials this year, with the ultimate goal of bringing new, effective treatments for RSV to patients.”
ReViral is progressing its lead drug candidate (RV521), a highly potent and orally bioavailable potential treatment for RSV infections. Pre-clinical and clinical studies have shown that RV521 is a best-in-class inhibitor of RSV in adult volunteers. RV521 is now poised to enter an international multicentre Phase IIa pediatric trial. This study will be followed by additional trials in adult stem cell transplant patients.
RSV is one of the most important respiratory pathogens, with 30 million infections and an estimated 200,000 deaths worldwide annually in children under five years alone. There are currently no approved RSV vaccines available, and there is an urgent need for improved therapeutics for this indication.
